Antipsychotic prescribing practices in Connecticut's public mental health system: rates of changing medications and prescribing styles.
about
Antipsychotic combinations for schizophreniaAntipsychotic monotherapy and polypharmacy in the naturalistic treatment of schizophrenia with atypical antipsychoticsA translational research approach to poor treatment response in patients with schizophrenia: clozapine-antipsychotic polypharmacyCost of antipsychotic polypharmacy in the treatment of schizophrenia.The effect of ethnicity on prescribing practice and treatment outcome in inpatients suffering from schizophrenia in Greece.Effectiveness of lurasidone in schizophrenia or schizoaffective patients switched from other antipsychotics: a 6-month, open-label, extension study.The role of long-acting injectable antipsychotics in schizophrenia: a critical appraisal.Routine outcomes monitoring to support improving care for schizophrenia: report from the VA Mental Health QUERI.A retrospective study of antipsychotic drug switching in a pediatric population.Incidence of tardive dyskinesia with atypical versus conventional antipsychotic medications: a prospective cohort studyPolypharmacy with antipsychotic drugs in patients with schizophrenia: trends in multiple health care systems.An audit of outpatient antipsychotic usage in the three health sectors of Auckland, New Zealand.Changes in antipsychotic drug prescribing by general practitioners in the United Kingdom from 1991 to 2000: a population-based observational study.Prevalence and correlates of antipsychotic polypharmacy: a systematic review and meta-regression of global and regional trends from the 1970s to 2009.Antipsychotic monotherapy among outpatients with schizophrenia treated with olanzapine or risperidone in Japan: a health care database analysisAntipsychotic treatment among youth in foster care.Switching antipsychotics: an updated review with a focus on quetiapine.Long-term antipsychotic polypharmacy in the VA health system: patient characteristics and treatment patterns.The effect of race-ethnicity on the comparative effectiveness of clozapine among Medicaid beneficiaries.Antipsychotic polypharmacy: a comprehensive evaluation of relevant correlates of a long-standing clinical practiceHigh-dose antipsychotic use in schizophrenia: a comparison between the 2001 and 2004 Research on East Asia Psychotropic Prescription (REAP) studies.Race and long-acting antipsychotic prescription at a community mental health center: a retrospective chart review.Racial and ethnic disparities in the treatment of a Medicaid population with schizophrenia.Antipsychotic polypharmacy in schizophrenia: benefits and risks.Racial and ethnic disparities in the use of antipsychotic medication: a systematic review and meta-analysis.Prevalence of and factors associated with antipsychotic polypharmacy in patients with serious mental illness: Findings from a cross-sectional study in an upper-middle-income country.Indications for and use of long-acting injectable antipsychotics: consideration from an inpatient setting.Trends in antipsychotic prescribing in schizophrenia in Auckland.Communities of color? Client-to-client racial concordance in the selection of mental health programs for Caucasians and African Americans.Predictors of early worsening after switch to aripiprazole: a randomized, controlled, open-label study.Impact of audit and feedback on antipsychotic prescribing in schizophrenia.Ethnic comparisons of antipsychotic use in schizophrenia.The effect of income and race on quality of psychiatric care in community mental health centers.Distance matters in choice of mental health program: policy implications for reducing racial disparities in public mental health care.Cost-utility analysis of treatment with olanzapine compared with other antipsychotic treatments in patients with schizophrenia in the pan-European SOHO study.Pharmacotherapy of first episode psychosis in Estonia: comparison with national and international treatment guidelines.The prescription of psychotropic drugs in psychiatric residential facilities: a national survey in Italy."Impact of drug-reimbursement policies on prescribing: A case-study of a newly marketed long-acting injectable antipsychotic among relapsed schizophrenia patients".Characteristics of Medicaid Recipients Receiving Persistent Antipsychotic Polypharmacy.Patient characteristics and process factors associated with antipsychotic polypharmacy in a nationwide sample of psychiatric inpatients in Italy.
P2860
Q24234513-D72B30D6-2E4B-436D-AD86-71BA91716F4BQ24811190-506CABC5-7BCD-427F-A5D5-EC289429578CQ30485065-6FEECD48-604D-4150-A8B0-CCA9E420D01DQ33327172-7A758536-794A-46C4-96A9-E2CEE05723D0Q33877886-62269B79-47C8-4755-8D7A-472EFD23A353Q34073723-C47CC796-42F4-4F16-851F-45331F93B0E1Q34418847-2322AC67-852D-4503-9D6D-A92B1132A889Q34680925-85310B21-CFBC-4925-858B-E4FF84848A30Q35011070-723022F2-55B4-4B6C-8911-F766FE294E3AQ35030003-D7FD00A1-E5E1-4610-A6D8-66101F422FBCQ35608522-A81D991A-AE70-4345-94DE-138074AEB384Q35707526-FF0360B6-4548-4F8F-B111-5B67C155E179Q35825831-8743091E-BFEB-4E2F-819E-06D2B4508ADBQ36057820-8CE075BC-EE5B-4EC1-A24B-13C35602ED83Q36065092-81CBC641-7A6F-42A5-A8B7-2C92DD25887FQ36071218-DA0FAD7B-9B7A-4FE9-B614-72467B38E8F0Q36276541-899B2FF1-9356-49B1-B6CF-5CA33B6CB068Q36905083-607A4D4A-7DEA-44CC-9FF1-1C3FCFF0D3DFQ37018470-76FE8525-5FB7-470F-8372-0F4D0FCB7138Q37029622-DD41416D-E9AB-435E-8B57-8A8C3F797A6FQ37156296-87BA8BCB-CEBC-4679-9513-A5F267DA0719Q37450910-D380EDBA-C222-492F-A5A6-991615DB7872Q37485253-D050A955-D517-46C2-A60E-6D22E201C38BQ37863093-20789E55-7076-4A14-AB61-11CE9C28A629Q38128722-CC7B07F1-73D3-436E-A954-4B135F60E1B1Q38972585-F3FDC434-A439-4168-A184-4D32A717747AQ39128141-6435E01A-EAA9-44DD-A8D6-DF0333EC4C23Q39756918-42BF7EDA-34B9-425F-953A-AFB9AEB3F078Q39984403-B7B27625-2900-4A3E-BAE0-B0D42EDDE100Q43161912-0CFBFE75-822E-44F3-B4E5-A21478C86465Q45789228-BD6FD3C1-552E-422C-B903-69C6CD9BAF79Q46382373-DE778A94-3E83-4354-8FFE-1B1C71A8A823Q46538504-073DC62D-DDCD-4BDB-8197-A01A75273ECFQ46563755-3AE7DFE6-D0B5-451B-AB0B-E7815044B90EQ46679446-01690935-186E-427C-A958-E4BBBCD85D50Q46721830-A6463319-546E-4F52-B3DD-BAF5172F15F3Q46934245-8A314A03-ED9F-4E0B-9FF6-241D5CE22EF2Q47424833-D2BE21A2-5B51-477C-95BC-0C877517DA92Q48321579-B9A4DB2F-331A-4211-8780-05786EEA1226Q50804521-26879F9E-FDA4-401B-8A8C-0C5DC42158F2
P2860
Antipsychotic prescribing practices in Connecticut's public mental health system: rates of changing medications and prescribing styles.
description
2002 nî lūn-bûn
@nan
2002年の論文
@ja
2002年学术文章
@wuu
2002年学术文章
@zh
2002年学术文章
@zh-cn
2002年学术文章
@zh-hans
2002年学术文章
@zh-my
2002年学术文章
@zh-sg
2002年學術文章
@yue
2002年學術文章
@zh-hant
name
Antipsychotic prescribing prac ...... ations and prescribing styles.
@en
Antipsychotic prescribing prac ...... ations and prescribing styles.
@nl
type
label
Antipsychotic prescribing prac ...... ations and prescribing styles.
@en
Antipsychotic prescribing prac ...... ations and prescribing styles.
@nl
prefLabel
Antipsychotic prescribing prac ...... ations and prescribing styles.
@en
Antipsychotic prescribing prac ...... ations and prescribing styles.
@nl
P2093
P1476
Antipsychotic prescribing prac ...... ations and prescribing styles.
@en
P2093
Arthur C Evans
Carlos T Jackson
Nancy H Covell
Susan M Essock
P356
10.1093/OXFORDJOURNALS.SCHBUL.A006920
P407
P577
2002-01-01T00:00:00Z